Clinical Trial: Alemtuzumab and Rituximab in Aplastic Anemia

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional




Official Title: Low-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic Anemia

Brief Summary: The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.